PAHO and GARDP Collaborate to Combat Antimicrobial Resistance in Latin America and the Caribbean

Partnership Aims to Improve Regional Antibiotic R&D, Manufacturing, and Access

The Pan American Health Organization (PAHO) and the Global Antibiotic Research & Development Partnership (GARDP) have signed an agreement to collaborate in the response to antimicrobial resistance (AMR) in Latin America and the Caribbean. Under the agreement, the organizations aim to improve regional antibiotic R&D, manufacturing, and access in the context of the emergence and spread of antibiotic-resistant infections.

Antimicrobial Resistance: A Growing Concern

According to a study recently published in The Lancet, antimicrobial resistance contributed to 322,000 deaths in Latin America and the Caribbean in 2021. That number is expected to rise to 650,000 by 2050, placing Latin America and the Caribbean among the regions with the highest AMR mortality rates across all ages.

Executive Director’s Statement

“The latest global estimates suggest that we are at a tipping point in the AMR crisis,” said Manica Balasegaram, Executive Director, GARDP. “If we take action now, we can avert tens of millions of deaths worldwide by 2050. R&D and access must work in tandem for a sustainable antibiotic ecosystem that serves patients in Latin America and the Caribbean and beyond.”

Objectives of the Partnership

In line with the agreement, GARDP and PAHO will focus on advancing regional access to existing and novel antimicrobials, optimizing medicines portfolios, leveraging regional structures for improved antimicrobial access, promoting regional innovation and production of antibiotics, and engaging in strategic dialogues for global R&D priorities. The agreement will also facilitate access to new products to treat serious bacterial infections, including sexually transmitted infections, a significant public health concern in Latin America and the Caribbean. The partnership will collaborate with existing regional initiatives, such as PAHO’s Regional Revolving Funds for pooled procurement and the PAHO Special Program, Innovation and Regional Production Platform.

Director’s Statement

“This agreement will allow PAHO to keep pursuing universal access to the medicines and technologies needed to cure drug-resistant infections while promoting regional innovation and production of antibiotics,” PAHO Director Jarbas Barbosa said. “We know communities living in vulnerable situations in Latin America and the Caribbean are hit hardest by AMR. We must ensure fair access to the best diagnostics, treatment, and prevention for all,” he added.

Joint Research Efforts

Leading up to the signing of this agreement, PAHO and GARDP have been working together to test the susceptibility of certain carbapenem-resistant bacteria in the region. The forthcoming findings will be used to inform optimal treatment of drug-resistant infections using certain antibiotics and to help expand regional efforts to increase access to antibiotics.

Conclusion

The partnership between PAHO and GARDP is a crucial step in combating antimicrobial resistance in Latin America and the Caribbean. By working together, the organizations aim to improve regional antibiotic R&D, manufacturing, and access, ultimately saving lives and preventing the spread of drug-resistant infections.

FAQs

* What is antimicrobial resistance (AMR)?
+ AMR is the ability of microorganisms, such as bacteria, viruses, and fungi, to resist the effects of antibiotics, making infections harder to treat and increasing the risk of treatment failure.
* What is the impact of AMR in Latin America and the Caribbean?
+ According to a study published in The Lancet, AMR contributed to 322,000 deaths in Latin America and the Caribbean in 2021, and this number is expected to rise to 650,000 by 2050.
* What is the goal of the partnership between PAHO and GARDP?
+ The partnership aims to improve regional antibiotic R&D, manufacturing, and access to combat AMR in Latin America and the Caribbean.